CN Patent

CN117043159A — Kras突变型癌症的治疗

Assigned to Lite Strategy Inc · Expires 2023-11-10 · 3y expired

What this patent protects

Patent listed against Ayvakit.

Drugs covered by this patent

Ayvakit (AVAPRITINIB) · Blueprint Medicines

Patent Metadata

Patent number: CN117043159A
Jurisdiction: CN
Classification: —
Expires: 2023-11-10
Drug substance claim: No
Drug product claim: No
Assignee: Lite Strategy Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.